CBB1007
Based on 2 publication(s) in Google Scholar
CBB1007 is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma.
For research use only. We do not sell to patients.
- CAS No.: 1379573-92-8
- Formula: C27H34N8O4
- Molecular Weight:534.61
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) CBB1007
More-
WB
Biological Activity
|
KDM1/LSD1 5.27 μM (IC50) |
CBB1007 (0-100 μM; 30 h; F9) inhibits F9 cell growth[2].
CBB1007 (5-20 μM; 14 days; hESCs) increases lipid droplet formation in hESCs during adipogenesis[1].
CBB1007 (5-20 μM; 14 days; hESCs) reduces LSD1 and histone H3 levels while increasing H3K4me2 in human embryonic stem cells (hESCs)[1].
CBB1007 (5-20 μM; 14 days; hESCs) upregulates adipocyte marker genes PPARγ-2 and C/EBPα in hESCs[1].
CBB1007 (0.5-20 μM; 24 h; F9) activates the expression of CHRM4 and SCN3A genes[2].
CBB1007 (10 μM) significantly blocks the demethylase activity of LSD1 on mono- and di-methylated H3K4, but not tri-methylated H3K4 or di-methylated H3K9[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:F9 cell
-
Concentration:1 μM, 5 μM, 10 μM, 50 μM, 100 μM
-
Incubation Time:30 h
-
Result:Cell growth was significantly inhibited.
-
Cell Line:hESCs
-
Concentration:5 μM, 10 μM, 20 μM
-
Incubation Time:14 days
-
Result:LSD1 and histone H3 expression decreased, while H3K4me2 levels increased with higher doses.
-
Cell Line:hESCs
-
Concentration:5 μM, 10 μM, 20 μM
-
Incubation Time:14 days
-
Result:LSD1 and histone H3 expression decreased, while H3K4me2 levels increased with higher doses.
-
Cell Line:hESCs
-
Concentration:5 μM, 10 μM, 20 μM
-
Incubation Time:14 days
-
Result:PPARγ-2 and C/EBPα expression increased with increasing doses.
-
Cell Line:F9 cell
-
Concentration:0.5 μM, 1 μM, 5 μM, 20 μM
-
Incubation Time:24 h
-
Result:The expression of CHRM4 and SCN3A genes were activated. And markedly induced the expression of genes for differentiation, such as FOXA2.
Chemical Information
-
CAS No. 1379573-92-8
-
Molecular Weight 534.61
-
Formula C27H34N8O4
-
SMILES
NC(N1CCN(CC1)CC2=CC(C(OC)=O)=CC(C(N3CCN(CC3)C(C4=CC=C(C=C4)C(N)=N)=O)=O)=C2)=N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Clin Exp Med
Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis. [Abstract]2025 Nov 25;26(1):33. PMID: 41286164 -
BMC Neurosci
Mechanism of LSD1 in oxygen-glucose deprivation/reoxygenation-induced pyroptosis of retinal ganglion cells via the miR-21-5p/NLRP12 axis. [Abstract]2022 Nov 10;23(1):63. PMID: 36357913
CBB1007 purchased from MedChemExpress. Usage Cited in: BMC Neurosci. 2022 Nov 10;23(1):63. [Abstract]
CBB1007 (CBB) elevates H3K4me2 expression in RGC-5 cells, after which miR-21-5p expression levels are increased .
Purity & Documentation
References
[1]. Xiong Y, et al. Inhibition of Lysine-Specific Demethylase-1 (LSD1/KDM1A) Promotes the Adipogenic Differentiation of hESCs Through H3K4 Methylation. Stem Cell Rev Rep. 2016;12(3):298-304. [Content Brief]
[2]. Wang J, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011 Dec 1;71(23):7238-49. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)